Showing results (51-60 of 77) with videos related to
Sort By:
Pageof 8
Cytotechnology|January 1, 1992
Viability measurements of hybridoma cells in suspension culturesJ M Coco-Martin, J W Oberink, T A van der Velden-de Groot, et al.Pharmaceutical Research|February 1, 1992
The influence of sucrose, dextran, and hydroxypropyl-beta-cyclodextrin as lyoprotectants for a freeze-dried mouse IgG2a monoclonal antibody (MN12)M E Ressing, W Jiskoot, H Talsma, et al.Cytotechnology|January 1, 1992
The potential of flow cytometric analysis for the characterization of hybridoma cells in suspension culturesJ M Coco-Martin, J W Oberink, T A van der Velden-de Groot, et al.Infection and Immunity|November 1, 1986
Immunogenic activity of gonococcal protein I in mice with three different lipoidal adjuvants delivered in liposomes and in complexesW Jiskoot, T Teerlink, M M Van Hoof, et al.Developments in Biological Standardization|January 1, 1986
Analytical, toxicological and immunological consequences of the use of N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide as coupling reagent for the preparation of meningococcal group C polysaccharide-tetanus toxoid conjugate as vaccine for human useE C Beuvery, G J Speijers, B I Lutz, et al.European Journal of Biochemistry|October 1, 1991
Non-random conformation of a mouse IgG2a monoclonal antibody at low pHW Jiskoot, M Bloemendal, B van Haeringen, et al.Hybridoma|October 1, 1992
Instability of a hybridoma cell line in a homogeneous continuous perfusion culture systemJ M Coco-Martin, J W Oberink, F Brunink, et al.Journal of Biotechnology|December 20, 1999
Rational medium design for Bordetella pertussis: basic metabolismM Thalen, J van den IJssel, W Jiskoot, et al.Biotechnology and Bioengineering|February 20, 1993
Effect of dilution rate on growth, productivity, cell cycle and size, and shear sensitivity of a hybridoma cell in a continuous cultureD E Martens, C D de Gooijer, C A van der Velden-de Groot, et al.Developments in Biological Standardization|January 1, 1986
Class 1/3 outer membrane protein vaccine against group B, type 15, subtype 16 meningococciJ T Poolman, E C Beuvery, C T Hopman, et al.Pageof 8